GSK recruits Clover Biopharmaceuticals in latest coronavirus effort
GSK initially announced plans to make its pandemic vaccine adjuvant platform technology available at the beginning of February.
Read More
Tag: COV-19
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
